ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
Emerging growth company
|
Smaller reporting company
|
Page
|
||
PART I
|
||
Item 1.
|
2 | |
Item 1A.
|
9
|
|
Item 1B.
|
22
|
|
Item 1C.
|
23 | |
Item 2.
|
24 | |
Item 3.
|
24
|
|
Item 4.
|
24
|
|
PART II
|
||
Item 5.
|
25
|
|
Item 6.
|
26
|
|
Item 7.
|
26
|
|
Item 7A.
|
31
|
|
Item 8.
|
31 | |
Item 9.
|
54
|
|
Item 9A.
|
54
|
|
Item 9B.
|
54
|
|
Item 9C.
|
55
|
|
PART III
|
||
Item 10.
|
55
|
|
Item 11.
|
55
|
|
Item 12.
|
55
|
|
Item 13.
|
56
|
|
Item 14.
|
56
|
|
PART IV
|
||
Item 15.
|
56
|
• |
We have undertaken activities to commercialize our products and patent portfolio in and outside the United States including VirnetX One™, War Room™, VirnetX Matrix™, GABRIEL Connection Technology™ and our Secured
Domain Name Registry and Technology. These statements may imply that the worldwide market for our commercialized products is large and will result in significant future revenue for us. However, commercialization of products such as ours is
subject to significant obstacles and risks and may prevent significant future revenues for us.
|
•
|
Direct sales efforts with larger users, particularly those engaged in defense and others govermental or national initiatives.
|
• |
Actively recruit partners in various vertical markets, including healthcare, finance, legal, government to help us expand our enterprise customer base.
|
• |
Promote our next-generation VirnetX One™ platform as a solution for delivering ZTNA, and securing enterprise applications, services, and infrastructure.
|
• | Combine with VirnetX One™ platform with technologies from the companies we have invested in, namely OmniTeq and OPMedia, to enhance their offerings and provide supplemental sales channels for VirnetX One™ |
• |
Continue to grow our technology licensing program to commercialize our intellectual property, including our GABRIEL Connection Technology™.
|
• |
Grow registration of VirnetX Secure Domain Names as the network segmentation component of our ZTNA solution. Establish VirnetX as the exclusive, universal registry of secure domain names and enable our customers
to act as registrars for their users and broker secure communication between devices.
|
• |
Promote War RoomTM video conferencing product in the general market for sale to end-user enterprises, directly and with partners,
with targeted promotions and other marketing programs to assist remote workers and offer an industry leading secure meeting solution.
|
• |
Promote VirnetX Matrix™ enterprise applications, services, and infrastructure.
|
• |
Unique patented technology. We are focused on developing innovative technology for securing real-time communications over the Internet and establishing the exclusive secure
domain name registry in the United States and other key markets around the world. Our unique solutions combine industry standard encryption methods and communication protocols with our patented techniques for automated DNS lookup
mechanisms. Our technology and patented approach enable users to create a secure communication link by generating secure domain names. We currently own approximately 205 total patents and pending applications, including 72 U.S.
patents/patent applications and 133 foreign patents/validations/pending applications. Our portfolio includes patents and pending patent applications in the United States and other key markets that support our secure domain name registry
service for the Internet.
|
• |
Scalable licensing business model. We are actively engaged in pursuing additional licensing agreements with industry participants OEMs, service providers and system
integrators within the IP-telephony, mobility, mobile-to-mobile communications, fixed-mobile convergence, and unified communications end-markets.
|
• |
Highly experienced research and development team. Our research and development team is comprised of nationally recognized network security and encryption technology
scientists and experts that have worked together as a team for over ten years. During their careers, this team has developed several cutting-edge technologies for U.S. national defense, intelligence, and civilian agencies, many of which
remain critical to our national security today. Prior to joining VirnetX, our team worked for Leidos, during which time they invented the core technology that is the foundation of our current technology and software. Based on the collective
knowledge and experience of our development team, we believe that we have one of the most experienced and sophisticated groups of security experts researching vulnerability and threats to real-time communication over the Internet and
developing solutions to mitigate these problems.
|
We have undertaken activities to commercialize our products and intellectual property in and outside the United States including
VirnetX OneTM, War RoomTM, VirnetX MatrixTM, GABRIEL Connection TechnologyTM and our Secured Domain Name Registry and Technology. We believe our product portfolio to secure devices and systems are
stable in areas such as City, County and State Governments, Healthcare, Finance, Legal, Oil and Gas, Medical, Law Enforcement, National Defense and related support industries. We continue to actively pursue new sales opportunities in and one of
United States.
During 2023, we actively engaged in discussions with certain third-parties to pitch the capabilities of VimetX OneTM. As a result of our efforts, we made a series of announcements with Solution Synergy, WeSecure, Samsung, Every Data Corporation, and Object Security We also announced new deployments of our VimetX MatrixTM product at City of Bridgeport, International Association of Certified ISAOs (IACI) and SkinWalker Ranch. Although there can be no assurance in this regard, the Company believes that there are opportunities for Company products' sales directly to, resale arrangements with and/or adoption as vendor standards by, one or more of these third parties.
• |
Patent Assignment. Leidos, unconditionally and irrevocably conveyed, transferred, assigned, and quitclaimed all its right, title, and interest in and to the patents and
patent applications, as specifically set forth in the assignment document recorded with the U.S. Patent Office, including, without limitation, the right to sue for past infringement.
|
• |
License to Leidos, Outside the Field of Use. Effective March 12, 2008, we granted to Leidos, a non-exclusive, royalty free, fully paid, perpetual, worldwide, irrevocable,
sub licensable and transferable right and license permitting Leidos, and its assignees to make, have made, import, use, offer for sale, and sell products and services covered by, and to make improvements to, the patents and patent
applications we acquired from Leidos, solely outside our field of use.
|
• |
Compensation Obligations. As consideration for the assignment of the patents and for the rights we obtained from Leidos, as amended, we are required to make payments to
Leidos, based on cash or certain other values generated from those patents. The amount of such payments depends upon the type of value generated, and certain categories are subject to maximums and other limitations. In 2010, we met our
maximum royalty payment requirement; however, Leidos is also entitled under certain circumstances to receive a portion of the proceeds paid to us for certain acquisitions of VirnetX and the settlement of certain patent infringement claims
of ours.
|
Item 1A. | Risk Factors |
• |
Long and unpredictable sales cycles.
|
• |
We have limited technical resources and are at an early stage in commercialization of our products.
|
• |
Intensely competitive market with established brand names.
|
• |
Our business has been, and may continue to be, negatively affected by shareholders intent upon alternate business strategies.
|
• |
Our products are subject to governmental export and import controls that could subject us to liability or impair our ability to compete in international markets.
|
• |
If we are not able to adequately protect our patent rights and trade secrets, our business would be negatively impacted.
|
• |
Time and resources required to accelerate transition to new product development and sales strategies targeting large enterprises and government customers;
|
• |
Customer adoption of our VirnetX OneTM platform and software products and services;
|
• |
The number of product license sales of VirnetX Warroom, VirnetX Matrix and associated services;
|
• |
Adoption of VirnetX OneTM platform by third party application providers of secure communications;
|
• |
Intensely competitive market with established brands that have larger customer bases, and greater resources than we do;
|
• |
Prolonged economic uncertainties or downturns, globally or in certain regions or industries, could materially adversely affect our business;
|
• |
Government export and import control regulations on selling products with encryption technology in certain international markets;
|
• |
The need to educate potential customers about our patent rights and our product and service capabilities;
|
• |
Our customers’ willingness to invest potentially substantial resources and modify their network infrastructures to take advantage of our products;
|
• |
Our customers’ budgetary constraints and timing of their budget cycles;
|
• |
Delays caused by customers’ internal review processes; and
|
• |
Long sales cycles may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.
|
• |
Implement an effective marketing strategy to promote awareness of our products;
|
• |
Attract and retain customers for our products;
|
• |
Generate revenues or profit from product sales;
|
• |
Provide appropriate levels of customer training and technical support for our products;
|
• |
Rapidly anticipate and adapt to changes in the market and evolving customer requirements;
|
• |
Protect our products from any system failures or other breaches.
|
• |
Power loss, transmission cable cuts and other telecommunications failures;
|
• |
Damage or interruption caused by fire, earthquake, and other natural disasters;
|
• |
Computer viruses, electronic break-ins, sabotage, vandalism or software defects; and
|
• |
Physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control.
|
• |
A staggered Board of Directors: Only one or two directors (of our five-person Board of Directors) will be up for election at any given annual meeting. This delays the ability of
stockholders to affect a change in control of us because it would take two annual meetings to effectively replace a majority of the Board of Directors.
|
• |
Blank check preferred stock: Our Board of Directors has the authority to establish the rights, preferences, and privileges of our 10,000,000 authorized, but unissued, shares of
preferred stock. Therefore, this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock
can be used to create a “poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of
Directors can do so in the future, very rapidly and without stockholder approval.
|
• |
Advance notice requirements for director nominations and for business to be brought before stockholder meetings: Stockholders wishing to submit director nominations or raise
matters to a vote of the stockholders must provide notice to us within very specific date windows and in very specific form to have the matter voted on at a stockholder meeting. This gives our Board of Directors and management more time to
react to stockholder proposals generally and could also permit us to disregard a stockholder proposal to the extent such proposal is not submitted in accordance with the bylaws.
|
• |
No stockholder actions by written consent: No stockholder or group of stockholders may take action by written consent. Along with the advance notice requirements described above,
this provision also gives our Board of Directors and management more time to react to proposed stockholder actions.
|
• |
Super majority requirement for stockholder amendments to the bylaws: Stockholder proposals to alter or amend our bylaws or to adopt new bylaws can only be approved by the
affirmative vote of at least 66 2/3% of the outstanding shares of our common stock.
|
• |
No ability of stockholders to call a special meeting of the stockholders: A special meeting of the stockholders, other than as required by statute, may be called at any time by the
Board of Directors, or by the chairman of the board, or by the president, and any power of stockholders to call a special meeting of stockholders is specifically denied. Accordingly, stockholders, even those who represent a significant
percentage of our shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.
|
• |
Annual variations, actual or anticipated, in our operating results;
|
• |
Significant changes in our management;
|
• |
Large purchases or sales of common stock or derivative transactions related to our stock;
|
• |
Actual or anticipated announcements of new products or services by us or competitors;
|
• |
General conditions in the markets in which we compete; and
|
• |
General social, political, economic, and financial conditions, including the significant volatility in the global financial markets.
|
Item 1B. |
Unresolved Staff Comments
|
Item 1C. |
Cybersecurity
|
Item 2. |
Properties
|
Item 3. |
Legal Proceedings
|
Item 4. |
Mine Safety Disclosure
|
Item 5. |
Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
|
*$100 invested on 12/31/18 in stock or index, including reinvestment of dividends. Fiscal year ending December 31. |
||
|
||
Copyright© 2024 Standard & Poor’s, a division of S&P Global. All rights reserved. |
12/18
|
12/19
|
12/20
|
12/21
|
12/22
|
12/23
|
|||||||||||||||||||
VirnetX Holding Corp
|
100.00
|
158.33
|
246.02
|
126.92
|
63.46
|
44.33
|
||||||||||||||||||
S&P 500
|
100.00
|
131.49
|
155.68
|
200.37
|
164.08
|
207.21
|
||||||||||||||||||
RDG Technology Composite
|
100.00
|
142.93
|
222.56
|
266.61
|
181.18
|
261.37
|
Item 6. |
[Reserved]
|
Item 7. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
Investments
Investments classified as available-for-sale are recorded at fair market value. Unrealized gains and losses are reported as other comprehensive income. Realized gains and losses are recorded in income in the period they are realized using
specific identification of each security's cost basis. We invest our excess cash primarily in highly liquid debt instruments including corporate, government and federal agency securities, with contractual maturities less than two years. By
policy, we limit the amount of credit exposure to any one issuer.
We have elected the investment measurement alternative for other investments without readily determinable fair values. During 2023, we invested $2,000 in L2 Holdings LLC and $500 in OP
Media Inc. These investments are carried at our initial cost less any impairment, because we do not have the ability to exercise significant influence over operating and financial matters. For these investments, we adjust the carrying value for
any purchases or sales of our ownership interests. Periodically, we evaluate these investments for impairment. If we identify an impairment, we reduce the carrying value for the impairment loss with a charge to earnings. We have not identified
any impairment as of December 31, 2023.
2023
|
2022
|
|||||||
Revenue
|
$
|
7
|
$
|
48
|
2023
|
2022
|
|||||||
Licensing costs
|
$
|
—
|
$
|
(4
|
)
|
2023
|
2022
|
|||||||
Research and Development
|
$
|
9,713
|
$
|
6,406
|
2023
|
2022
|
|||||||
Selling, General and Administrative
|
$
|
21,739
|
$
|
15,722
|
2023
|
2022
|
|||||||
Interest and Other Income
|
$
|
3,495
|
$
|
1,848
|
Year
Ended
December
31,
2023
|
Year
Ended
December
31,
2022
|
|||||||
United States federal statutory rate
|
21.00
|
%
|
21.00
|
%
|
||||
State taxes, net of federal benefit
|
(0.01
|
)%
|
(0.55
|
)%
|
||||
Valuation allowance
|
(20.31
|
)%
|
(91.21
|
)%
|
||||
Stock based compensation
|
(0.58
|
)%
|
(9.44
|
)%
|
||||
R&D Credit
|
2.20
|
%
|
1.22
|
%
|
||||
Other
|
(2.03
|
)%
|
(0.29
|
)%
|
||||
Effective income tax rate
|
0.28
|
%
|
(79.27
|
)%
|
Item 7A. |
Quantitative and Qualitative Disclosures about Market Risk
|
Page
|
|
33
|
|
35
|
|
36
|
|
37
|
|
38
|
|
39
|
|
40
|
Description of the Matter
|
Other Investments
As discussed in Note 2 to the financial statements, the Company purchased equity interests in two private entities. Given that the entities
do not have a readily determinable fair market value, management must consider various factors, including the Company’s ability to apply significant influence to the overall operations of the entities, in determining the classification
and the initial value of the Other Investments. In addition, management must also evaluate the investments as of each reporting period to determine if there are any factors that would impact the recognized value of Other Investments.
Our determination that the classification and the valuation of Other Investments is a critical audit matter results from the significant
judgment by management when assessing the recognition method of the initial purchase as well as the ongoing analysis of the valuation of the investments. This in turn led to a high degree of auditor judgment, subjectivity, and effort in
performing procedures relating to management’s assessment of the initial recognition and valuation of Other Investments.
|
Audit Procedures
|
Our principal audit procedures related to the Company’s Other Investments included the following:
- We evaluated management’s analysis regarding their ability to apply significant influence in the operations of the entities by obtaining information of the ownership percentage of the entities, composition of the respective
boards, and any other relevant factors in determining their recognition method being recognized as cost in accordance with Accounting Standards Codification 321.
- We also evaluated management’s assessment of impairment factors or any observable transactions from inception of the investments through year-end to determine whether an adjustment in the recognized value was necessary. This
includes reviewing management’s internal analysis as well as any publicly available data regarding any factors or events that could impact the entities’ values.
|
As of
December 31, 2023
|
As of
December 31, 2022
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Investments available for sale
|
|
|
||||||
Accounts receivables
|
|
|
||||||
Prepaid expenses and other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
Prepaid expenses and other assets
|
|
|
||||||
Property and equipment, net
|
|
|
||||||
Other investments
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and accrued liabilities
|
$
|
|
$
|
|
||||
Accrued payroll and related expenses
|
|
|
||||||
Other liabilities, current
|
|
|
||||||
Total current liabilities
|
|
|
||||||
Other liabilities
|
|
|
||||||
Total liabilities
|
|
|
||||||
Commitments and contingencies (Note 4)
|
||||||||
Stockholders’ equity:
|
||||||||
Preferred stock, par value $
|
|
|
||||||
Common stock, par value $
|
||||||||
Authorized:
|
||||||||
Additional paid-in capital
|
|
|
||||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
Total stockholders’ equity
|
|
|
||||||
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
|
Year Ended
December 31, 2023
|
Year Ended
December 31, 2022
|
||||||
Revenue
|
$
|
|
$
|
|
||||
Operating expense:
|
||||||||
Licensing costs
|
|
(
|
)
|
|||||
Research and development
|
|
|
||||||
Selling, general and administrative expenses
|
|
|
||||||
Total operating expense
|
|
|
||||||
(Loss) from operations
|
(
|
)
|
(
|
)
|
||||
Interest and other income, net
|
|
|
||||||
(Loss) before taxes
|
(
|
)
|
(
|
)
|
||||
Income tax (provision) benefit
|
|
(
|
)
|
|||||
Net (loss)
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Basic (loss) per share
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Diluted (loss) per share
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Weighted average shares outstanding basic
|
|
|
||||||
Weighted average shares outstanding diluted
|
|
|
|
Year Ended
December 31, 2023
|
Year Ended
December 31, 2022
|
||||||
Net (loss)
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Other comprehensive (loss) income, net of tax:
|
||||||||
Change in unrealized (loss) gain on investments, net
|
|
(
|
)
|
|||||
Change in foreign currency translation, net
|
(
|
)
|
|
|||||
Total other comprehensive (loss) gain, net of tax
|
|
(
|
)
|
|||||
Comprehensive (loss)
|
$
|
(
|
)
|
$
|
(
|
)
|
Year Ended |
||||||||
December 31, |
||||||||
2023
|
2022
|
|||||||
Total shareholders’ equity, beginning balances
|
$
|
|
$
|
|
||||
Common stock and additional paid-in capital:
|
||||||||
Beginning balances
|
|
|
||||||
Common stock issued for options/RSUs/RS, net
|
(
|
)
|
(
|
)
|
||||
Stock-based compensation
|
|
|
||||||
Ending balances
|
|
|
||||||
Accumulated deficit
|
||||||||
Beginning balances
|
(
|
)
|
(
|
)
|
||||
Net (loss)
|
(
|
)
|
(
|
)
|
||||
Dividends
|
(
|
)
|
|
|||||
Ending balances
|
(
|
)
|
(
|
)
|
||||
Accumulated other comprehensive loss:
|
||||||||
Beginning balances
|
(
|
)
|
(
|
)
|
||||
Change in unrealized investment (loss) gain, net
|
|
(
|
)
|
|||||
Change in foreign currency translation, net
|
(
|
)
|
|
|||||
Ending balances
|
(
|
)
|
(
|
)
|
||||
Total shareholders’ equity, ending balances
|
$
|
|
$
|
|
||||
Dividends per share
|
$ | $ |
|
Year Ended
December 31, 2023
|
Year Ended
December 31, 2022
|
||||||
Cash flows from operating activities:
|
||||||||
Net (loss)
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Adjustments to reconcile net (loss) to net cash from operating activities:
|
||||||||
Depreciation
|
|
|
||||||
Stock-based compensation
|
|
|
||||||
Bad debt
|
||||||||
Deferred income taxes
|
|
|
||||||
Changes in assets and liabilities:
|
||||||||
Prepaid expenses and other current assets
|
(
|
)
|
|
|||||
Accounts payable and accrued liabilities
|
|
|
||||||
Other liabilities
|
|
(
|
)
|
|||||
Accrued payroll and related expenses
|
|
|
||||||
Accrued licensing costs
|
|
(
|
)
|
|||||
Accounts receivable
|
(
|
)
|
|
|||||
Prepaid income taxes
|
|
(
|
)
|
|||||
Net cash used in operating activities
|
(
|
)
|
(
|
)
|
||||
Cash flows from investing activities:
|
||||||||
Purchase of property and equipment
|
(
|
)
|
|
|||||
Purchase of investments at cost
|
( |
) | ||||||
Purchase of investments
|
(
|
)
|
(
|
)
|
||||
Proceeds from sale or maturity of investments
|
|
|
||||||
Net cash provided by (used in) investing activities
|
|
(
|
)
|
|||||
Cash flows from financing activities:
|
||||||||
Dividend
|
( |
) | ||||||
Withholding taxes paid on cashless exercise of restricted stock and restricted stock units
|
(
|
)
|
(
|
)
|
||||
Net cash used in financing activities
|
(
|
)
|
(
|
)
|
||||
Net (decrease) in cash and cash equivalents
|
(
|
)
|
(
|
)
|
||||
Cash and cash equivalents, beginning of period
|
|
|
||||||
Cash and cash equivalents, end of period
|
$
|
|
$
|
|
||||
Cash paid for income taxes
|
$
|
|
$
|
|
December 31
|
||||||||
2023
|
2022
|
|||||||
Office furniture
|
$
|
|
$
|
|
||||
Computer equipment
|
|
|
||||||
Total
|
|
|
||||||
Less accumulated depreciation
|
(
|
)
|
(
|
)
|
||||
Total property and equipment, net
|
$
|
|
$
|
|
Options Outstanding
|
Options Vested and Exercisable
|
|||||||||||||||||||||||
Range of
Exercise Prices |
Number
Outstanding
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise
Price
|
Number
Exercisable
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise
Price
|
||||||||||||||||||
$ |
$ |
$ |
||||||||||||||||||||||
$
|
|
|
$
|
|
|
|
$
|
|
||||||||||||||||
$
|
|
|
$
|
|
|
|
$
|
|
||||||||||||||||
|
|
$
|
|
|
|
$
|
|
Options
|
||||||||||||||||
Number of
Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Aggregate
Intrinsic
Value
|
|||||||||||||
Outstanding, December 31, 2021
|
|
$
|
|
—
|
$
|
—
|
||||||||||
Options granted
|
|
|
—
|
—
|
||||||||||||
Options exercised
|
|
|
—
|
—
|
||||||||||||
Options cancelled
|
(
|
)
|
|
—
|
—
|
|||||||||||
Outstanding, December 31, 2022
|
|
$
|
|
—
|
$
|
|
||||||||||
Options granted
|
|
|
—
|
—
|
||||||||||||
Options exercised
|
|
|
—
|
—
|
||||||||||||
Options cancelled
|
(
|
)
|
|
—
|
—
|
|||||||||||
Outstanding, December 31, 2023
|
|
$
|
|
|
$
|
|
||||||||||
Options exercisable, December 31, 2023
|
|
$
|
|
|
$
|
|
RSUs
|
||||||||||||
Number of
RSUs
|
Weighted
Average
Grant Date
Fair Value
|
Aggregate
Intrinsic
Value
|
||||||||||
Outstanding, December 31, 2021
|
|
$
|
|
$
|
|
|||||||
RSUs granted
|
|
|
—
|
|||||||||
RSUs vested
|
(
|
)
|
|
—
|
||||||||
RSUs cancelled
|
|
|
—
|
|||||||||
Outstanding, December 31, 2022
|
|
$
|
|
$
|
|
|||||||
RSUs granted
|
|
|
—
|
|||||||||
RSUs vested
|
(
|
)
|
|
—
|
||||||||
RSUs cancelled |
— | |||||||||||
Outstanding, December 31, 2023
|
|
$
|
|
$
|
|
Restricted Stock
|
||||||||||||
|
Number of
Restricted Stock
|
Weighted
Average
Grant Date
Fair Value
|
Aggregate
Intrinsic
Value
|
|||||||||
Outstanding, December 31, 2022
|
|
$
|
|
$
|
|
|||||||
Restricted stock granted
|
|
|
—
|
|||||||||
Restricted stock vested
|
(
|
)
|
|
—
|
||||||||
Restricted stock cancelled
|
(
|
)
|
|
—
|
||||||||
Outstanding, December 31, 2023
|
|
$
|
|
$
|
|
Stock-Based Compensation by Type of Award
|
Year Ended
December 31, 2023
|
Year Ended
December 31, 2022
|
||||||
Stock options
|
$
|
|
$
|
|
||||
RSUs
|
|
|
||||||
Restricted stock |
||||||||
Total stock-based compensation expense
|
$
|
|
$
|
|
Year Ended
December 31, 2023
|
Year Ended
December 31, 2022
|
|||||||
Expected stock price volatility
|
|
%
|
|
%
|
||||
Risk-free interest rate
|
|
%
|
|
%
|
||||
Expected life term
|
|
|
||||||
Expected dividends
|
|
%
|
|
%
|
Year Ended December 31, | ||||||||
2023
|
2022
|
|||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Basic weighted average number of shares outstanding
|
||||||||
Effect of dilutive securities
|
|
|
||||||
Diluted weighted average number of shares outstanding
|
|
|
||||||
Basic (loss) earnings per share
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Diluted (loss) earnings per share
|
$
|
(
|
)
|
$
|
(
|
)
|
Warrants
Issued
|
Exercise
Price
|
Outstanding and
Exercisable
December 31, 2022
|
Issued
|
Exercised
|
Terminated /
Cancelled
|
Outstanding and
Exercisable
December 31, 2023
|
Expiration Date
|
|||||||||||||||||||||
|
$
|
|
|
|
|
|
|
|
Year Ended
December 31, 2023 |
Year Ended
December 31, 2022 |
|||||||
Current:
|
||||||||
Federal
|
$
|
|
$
|
|
||||
State
|
|
|
||||||
Foreign
|
||||||||
|
|
|
||||||
Deferred:
|
||||||||
Federal
|
(
|
)
|
|
|||||
State
|
(
|
)
|
|
|||||
( |
) | |||||||
Total income tax (benefit) provision
|
$ | ( |
) |
$
|
|
Year Ended
December 31, 2023 |
Year Ended
December 31, 2022 |
|||||||
United States federal statutory rate
|
|
%
|
|
%
|
||||
State taxes, net of federal benefit
|
(
|
)%
|
(
|
)%
|
||||
Valuation allowance
|
(
|
)%
|
(
|
)%
|
||||
Stock based compensation
|
(
|
)%
|
(
|
)%
|
||||
R&D Credit
|
|
%
|
|
%
|
||||
Other
|
(
|
)%
|
(
|
)%
|
||||
Effective income tax rate
|
% |
(
|
)%
|
As of
December 31, 2023 |
As of
December 31, 2022 |
|||||||
Deferred tax assets:
|
||||||||
Reserves and accruals
|
$
|
|
$
|
|
||||
Research and development credits and other credits
|
|
|
||||||
Net operating loss carry forward
|
|
|
||||||
Stock based compensation
|
|
|
||||||
Other
|
|
|
||||||
Total deferred tax assets
|
$
|
|
$
|
|
||||
Valuation allowance
|
(
|
)
|
(
|
)
|
||||
Deferred tax assets after valuation allowance
|
|
|
||||||
Total deferred tax liability – depreciation and
amortization
|
|
|
||||||
Net deferred tax assets
|
$
|
|
$
|
|
December 31, 2023
|
||||||||||||||||||||||||
Adjusted
Cost |
Unrealized
Gains |
Unrealized
Losses |
Fair
Value |
Cash
and Cash Equivalents |
Investments
Available for Sale |
|||||||||||||||||||
Cash
|
$
|
|
$
|
—
|
$
|
—
|
$
|
|
$
|
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
|
|
|
|
|
|
||||||||||||||||||
U.S. agency and treasury securities
|
|
|
(
|
)
|
|
|
|
|||||||||||||||||
|
|
(
|
)
|
|
|
|
||||||||||||||||||
Total
|
$
|
|
$
|
27
|
$
|
(18
|
)
|
$
|
|
$
|
|
$
|
|
December 31, 2022
|
||||||||||||||||||||||||
Adjusted
Cost |
Unrealized
Gains |
Unrealized
Losses |
Fair
Value |
Cash
and Cash Equivalents |
Investments
Available for Sale |
|||||||||||||||||||
Cash
|
$
|
|
$
|
—
|
$
|
—
|
$
|
|
$
|
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
|
|
|
|
|
|
||||||||||||||||||
U.S. agency and treasury securities
|
( |
) | ||||||||||||||||||||||
|
|
(
|
)
|
|
|
|
||||||||||||||||||
Total
|
$
|
|
$
|
9
|
$
|
(386
|
)
|
$
|
|
$
|
|
$
|
|
Due in 2024
|
$
|
|
||
Due in 2025
|
$
|
|
||
Due in 2026
|
$
|
|
||
Due in 2027
|
$
|
|
||
Due in 2028
|
$
|
|
||
Thereafter
|
$
|
|
||
Total undiscounted lease liability
|
$
|
|
||
Less: imputed interest |
$ | ( |
) | |
Total lease liability |
$ |
Item 9. |
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
|
Item 9A. |
Controls and Procedures
|
Item 9C. |
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
|
Item 10. |
Directors, Executive Officers and Corporate Governance
|
Item 11. |
Executive Compensation
|
Item 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
Plan Category
|
Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options and
RSUs
|
Weighted-Average
Exercise Price of
Outstanding
Options and RSUs
|
Number of
Securities
Remaining
Available for
Future Issuance
Under Equity
Compensation
Plans
|
|||||||||
Equity compensation plans approved by security holders
|
347,467
|
$
|
89.32
|
225,778
|
||||||||
Equity compensation plans not approved by security holders
|
—
|
—
|
||||||||||
Total
|
347,467
|
$
|
89.32
|
225,778
|
Item 13. |
Certain Relationships and Related Transactions, and Director Independence
|
Item 14. |
Principal Accounting Fees and Services
|
Item 15. |
Exhibits and Financial Statement Schedules
|
(a) |
The following documents are filed as part of this Annual Report on Form 10-K
|
(1) |
Financial Statements: See the Index to Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K.
|
(2) |
Financial Statement Schedule: Financial statement schedules are omitted because they are not applicable, or the required information is shown in the financial statements or
notes thereto. All other schedules are omitted because of the absence of conditions under which they are required or because the required information is given in the financial statements or the notes thereto.
|
(3) |
Exhibits: The documents listed in the Exhibit Index of this Annual Report on Form 10-K are incorporated by reference or are filed with this Annual Report on Form 10-K, in
each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).
|
Exhibit
Number
|
Description
|
Incorporated by reference herein
|
|
|||
Form
|
Exhibit No.
|
Filing Date
|
File No.
|
Filed Herewith
|
||
3.1
|
8-K
|
3.1
|
11/01/2007
|
000-26895
|
|
|
3.2
|
8-K
|
3.1
|
10/25/2023
|
001-33852
|
||
3.3
|
8-K
|
3.1
|
1/27/2023
|
001-33852
|
|
|
4.2
|
S-3
|
4.1
|
07/30/2018
|
333-226413
|
|
|
4.3
|
S-3
|
4.2
|
07/30/2018
|
333-226413
|
|
|
4.4
|
S-3
|
4.4
|
07/30/2018
|
333-226413
|
|
|
4.5
|
10-K
|
4.6
|
03/16/2020
|
001-33852
|
|
|
10.1
|
10-K
|
10.1
|
03/18/2019
|
001-33852
|
|
|
10.2*
|
10-Q
|
10.2
|
05/10/2012
|
001-33852
|
|
|
10.3*
|
10-Q
|
4.5
|
05/10/2011
|
001-33852
|
|
|
10.4*
|
10-Q
|
10.3
|
05/10/2012
|
001-33852
|
|
|
10.5*
|
DEF 14A
|
Appendix A
|
04/13/2021
|
001-33852
|
||
10.6*
|
S-8
|
10.1
|
06/15/2023
|
333-272677
|
||
10.7*
|
10-K
|
10.6
|
03/02/2015
|
001-33852
|
||
10.8*
|
10-K
|
10.7
|
03/02/2015
|
001-33852
|
||
10.9*
|
10-Q
|
10.2
|
08/11/2023
|
001-33852
|
|
|
10.10
|
8-K
|
10.4
|
07/12/2007
|
000-26895
|
|
|
10.11**
|
8-K
|
10.6
|
07/12/2007
|
000-26895
|
|
|
10.12
|
8-K
|
10.1
|
03/18/2008
|
001-33852
|
|
|
10.13
|
8-K
|
10.5
|
07/12/2007
|
000-26895
|
|
|
10.14
|
8-K
|
10.7
|
07/12/2007
|
000-26895
|
|
|
10.15
|
8-K
|
10.8
|
07/12/2007
|
000-26895
|
|
|
10.16**
|
10-Q/A
|
10.1
|
01/31/2011
|
001-33852
|
|
|
10.17**
|
10-K
|
10.23
|
03/02/2015
|
001-33852
|
|
|
10.18*
|
10-Q
|
10.1
|
11/08/2021
|
001-33852
|
|
|
10.19*
|
Offer Letter by and between Darl C. McBride and the Company, dated as of December 22, 2023.
|
X
|
||||
10.20
|
8-K
|
10.1
|
03/30/2023
|
001-33852
|
10.21
|
10-Q
|
10.2
|
05/15/2023
|
001-33852
|
||
10.22*
|
Outside Director Compensation Policy, as amended.
|
X
|
||||
21.1
|
10-K
|
21.1
|
03/16/2021
|
001-33852
|
|
|
Consent of Farber Hass Hurley LLP, Independent Registered Public Accounting Firm.
|
|
|
|
|
X
|
|
24.1
|
Power of Attorney (contained on signature page hereto)
|
|
|
|
|
X
|
Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act.
|
|
|
|
|
X
|
|
Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act.
|
|
|
|
|
X
|
|
Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
|
X
|
|
Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
X
|
|
97.1*
|
Compensation Recovery Policy of the Company as adopted November 8, 2023.
|
X
|
||||
101.INS
|
XBRL Instance Document
|
|
|
|
|
X
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
X
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
X
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
X
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
X
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
|
|
|
|
X
|
* |
Indicates management contract or compensatory plan.
|
** |
Confidential treatment has been granted by the SEC as to certain portions of this exhibit.
|
*** |
Portions of this exhibit have been omitted pending a determination by the SEC as to whether these portions should be granted confidential treatment.
|
† |
The certifications attached as Exhibit 32.1 and 32.2 that accompany this Report are not deemed filed with the Securities and Exchange Commission and are not to be
incorporated by reference into any filing of VirnetX Holding Corporation under the Securities Act or the Exchange Act, whether before or after the date of this Report, irrespective of any general incorporation language contained in such
filing.
|
VirnetX Holding Corporation
|
||
By:
|
/s/ Kendall Larsen
|
|
Name: Kendall Larsen
|
||
Title: Chief Executive Officer and President
|
||
Dated: March 15, 2024
|
Name
|
|
Capacity
|
|
Date
|
/s/Kendall Larsen
|
Director, Chief Executive Officer and President
|
March 15, 2024
|
||
Kendall Larsen
|
(Principal Executive Officer)
|
|||
/s/Katherine Allanson
|
Chief Financial Officer
|
March 15, 2024
|
||
Katherine Allanson
|
(Principal Financial Officer and
Principal Accounting Officer)
|
|||
/s/Robert D. Short III
|
Director
|
March 15, 2024
|
||
Robert D. Short III
|
||||
/s/Gary Feiner
|
Director
|
March 15, 2024
|
||
Gary Feiner
|
||||
/s/Michael F. Angelo
|
Director
|
March 15, 2024
|
||
Michael F. Angelo
|
||||
/s/Thomas M. O’Brien
|
Director
|
March 15, 2024
|
||
Thomas M. O’Brien
|